Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Letter to the Editor Regarding "Can Early Postoperative O-(2-18FFluoroethyl)-l-Tyrosine Positron Emission Tomography After Resection of Glioblastoma Predict the Location of Later Tumor Recurrence?"

Fang X, Kong W, Yu Z, Qiu J, Duan H.

World Neurosurg. 2019 Mar;123:469. doi: 10.1016/j.wneu.2018.10.050. No abstract available.

PMID:
30832182
2.
3.

Can Early Postoperative O-(2-18FFluoroethyl)-l-Tyrosine Positron Emission Tomography After Resection of Glioblastoma Predict the Location of Later Tumor Recurrence?

Buchmann N, Gempt J, Ryang YM, Pyka T, Kirschke JS, Meyer B, Ringel F.

World Neurosurg. 2019 Jan;121:e467-e474. doi: 10.1016/j.wneu.2018.09.139. Epub 2018 Sep 27.

PMID:
30267942
4.

(18)F-Fluoroethyl-l-Thyrosine Positron Emission Tomography to Delineate Tumor Residuals After Glioblastoma Resection: A Comparison with Standard Postoperative Magnetic Resonance Imaging.

Buchmann N, Kläsner B, Gempt J, Bauer JS, Pyka T, Delbridge C, Meyer B, Krause BJ, Ringel F.

World Neurosurg. 2016 May;89:420-6. doi: 10.1016/j.wneu.2016.02.032. Epub 2016 Feb 15.

PMID:
26893043
5.

Monitoring of radiochemotherapy in patients with glioblastoma using O-(2-¹⁸Fluoroethyl)-L-tyrosine positron emission tomography: is dynamic imaging helpful?

Piroth MD, Liebenstund S, Galldiks N, Stoffels G, Shah NJ, Eble MJ, Coenen HH, Langen KJ.

Mol Imaging. 2013 Sep;12(6):388-95.

PMID:
23981784
6.

O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma.

Pöpperl G, Goldbrunner R, Gildehaus FJ, Kreth FW, Tanner P, Holtmannspötter M, Tonn JC, Tatsch K.

Eur J Nucl Med Mol Imaging. 2005 Sep;32(9):1018-25. Epub 2005 May 5.

PMID:
15877226
7.

Dynamic O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy.

Ceccon G, Lohmann P, Stoffels G, Judov N, Filss CP, Rapp M, Bauer E, Hamisch C, Ruge MI, Kocher M, Kuchelmeister K, Sellhaus B, Sabel M, Fink GR, Shah NJ, Langen KJ, Galldiks N.

Neuro Oncol. 2017 Feb 1;19(2):281-288. doi: 10.1093/neuonc/now149.

8.

Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI.

Galldiks N, Langen KJ, Holy R, Pinkawa M, Stoffels G, Nolte KW, Kaiser HJ, Filss CP, Fink GR, Coenen HH, Eble MJ, Piroth MD.

J Nucl Med. 2012 Jul;53(7):1048-57. doi: 10.2967/jnumed.111.098590. Epub 2012 May 29. Erratum in: J Nucl Med. 2013 Oct;54(10):1846.

9.

Correlation of Dynamic O-(2-[18F]Fluoroethyl)-L-Tyrosine Positron Emission Tomography, Conventional Magnetic Resonance Imaging, and Whole-Brain Histopathology in a Pretreated Glioblastoma: A Postmortem Study.

Lohmann P, Piroth MD, Sellhaus B, Weis J, Geisler S, Oros-Peusquens AM, Mohlberg H, Amunts K, Shah NJ, Galldiks N, Langen KJ.

World Neurosurg. 2018 Nov;119:e653-e660. doi: 10.1016/j.wneu.2018.07.232. Epub 2018 Aug 2.

PMID:
30077752
10.

Evaluation of O-(2-[18F]-Fluoroethyl)-L-Tyrosine in the Diagnosis of Glioblastoma.

Benouaich-Amiel A, Lubrano V, Tafani M, Uro-coste E, Gantet P, Sol JC, Roux F, Bousquet P, Julian A, Sabatier J, Tremoulet M, Cances-Lauwers V, Delisle MB, Clanet M, Esquerré JP, Payoux P.

Arch Neurol. 2010 Mar;67(3):370-2. doi: 10.1001/archneurol.2010.22.

PMID:
20212242
11.

Patterns of failure for patients with glioblastoma following O-(2-[18F]fluoroethyl)-L-tyrosine PET- and MRI-guided radiotherapy.

Lundemann M, Costa JC, Law I, Engelholm SA, Muhic A, Poulsen HS, Munck Af Rosenschold P.

Radiother Oncol. 2017 Mar;122(3):380-386. doi: 10.1016/j.radonc.2017.01.002. Epub 2017 Jan 19.

PMID:
28110959
12.

[Synthesis and preliminary studies of O-(2-[18F] fluoroethyl)-L-tyrosine as a positron emission tomography imaging agent].

Dang YH, Wang SZ, Cheng X, Zhou Q.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2002 Aug;24(4):370-2. Chinese.

PMID:
12905655
13.

Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET.

Kebir S, Fimmers R, Galldiks N, Schäfer N, Mack F, Schaub C, Stuplich M, Niessen M, Tzaridis T, Simon M, Stoffels G, Langen KJ, Scheffler B, Glas M, Herrlinger U.

Clin Cancer Res. 2016 May 1;22(9):2190-6. doi: 10.1158/1078-0432.CCR-15-1334. Epub 2015 Dec 16.

14.

Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.

Bette S, Gempt J, Delbridge C, Kirschke JS, Schlegel J, Foerster S, Huber T, Pyka T, Zimmer C, Meyer B, Ringel F.

World Neurosurg. 2016 May;89:230-9. doi: 10.1016/j.wneu.2016.01.085. Epub 2016 Mar 9.

PMID:
26855307
15.

Synthesis and in vitro evaluation of 18F labeled tyrosine derivatives as potential positron emission tomography (PET) imaging agents.

Wang L, Qu W, Lieberman B, Ploessl K, Kung HF.

Bioorg Med Chem Lett. 2010 Jun 15;20(12):3482-5. doi: 10.1016/j.bmcl.2010.05.007.

PMID:
20529679
16.

The Value of 5-Aminolevulinic Acid in Low-grade Gliomas and High-grade Gliomas Lacking Glioblastoma Imaging Features: An Analysis Based on Fluorescence, Magnetic Resonance Imaging, 18F-Fluoroethyl Tyrosine Positron Emission Tomography, and Tumor Molecular Factors.

Jaber M, Wölfer J, Ewelt C, Holling M, Hasselblatt M, Niederstadt T, Zoubi T, Weckesser M, Stummer W.

Neurosurgery. 2016 Mar;78(3):401-11; discussion 411. doi: 10.1227/NEU.0000000000001020.

17.

Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy.

Piroth MD, Holy R, Pinkawa M, Stoffels G, Kaiser HJ, Galldiks N, Herzog H, Coenen HH, Eble MJ, Langen KJ.

Radiother Oncol. 2011 May;99(2):218-24. doi: 10.1016/j.radonc.2011.03.006. Epub 2011 Apr 16.

PMID:
21497925
18.

Comparison of O-(2-18F-Fluoroethyl)-L-Tyrosine Positron Emission Tomography and Perfusion-Weighted Magnetic Resonance Imaging in the Diagnosis of Patients with Progressive and Recurrent Glioma: A Hybrid Positron Emission Tomography/Magnetic Resonance Study.

Verger A, Filss CP, Lohmann P, Stoffels G, Sabel M, Wittsack HJ, Kops ER, Galldiks N, Fink GR, Shah NJ, Langen KJ.

World Neurosurg. 2018 May;113:e727-e737. doi: 10.1016/j.wneu.2018.02.139. Epub 2018 Mar 3.

PMID:
29510293
19.
20.

An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases.

Grosu AL, Astner ST, Riedel E, Nieder C, Wiedenmann N, Heinemann F, Schwaiger M, Molls M, Wester HJ, Weber WA.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1049-58. doi: 10.1016/j.ijrobp.2010.07.002. Epub 2011 May 11.

PMID:
21570201

Supplemental Content

Support Center